Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin as an Adjunct to Conventional DMARDs in Rheumatoid Arthritis
NCT07901309Phase 2Not yet recruiting
- Sponsor
- Tanta University
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in rheumatoid arthritis (RA), sponsored by Tanta University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07901309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901309.